Pilot study of a pediatric metronomic 4-drug regimen

Nicolas André¹,², Sylvie Abed¹, Daniel Orbach³, Corinne Armari Alla⁴, Laetitia Padovani⁵, Eddy Pasquier²,⁶, Jean Claude Gentet¹, Arnauld Verschuuren¹,²

¹ Service d’Hématologie et Oncologie Pédiatrique, Hôpital pour Enfants de La Timone, Marseille, France
² Metronomics Global Health Initiative, Marseille, France
³ Service d’Oncologie Pédiatrique, Institut Curie, Paris, France
⁴ Service d’Oncologie Pédiatrique, Grenoble, France
⁵ Service de Radiothérapie, Hôpital de La Timone, Marseille, France
⁶ Children’s Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW, Australia

Correspondence to: Nicolas André MD, PhD, email: Nicolas.andre@ap-hm.fr

Keywords: metronomic chemotherapy, pediatric oncology, angiogenesis, immune system

Received: November 18, 2011, Accepted: December 5, 2011, Published: December 5, 2011

ABSTRACT:

Background: Metronomic chemotherapy (MC) is defined as the frequent administration of chemotherapy at doses below the maximal tolerated dose and with no prolonged drug-free break. MC is gaining interest as an alternative strategy to fight resistant cancer.

Objective: to assess the safety of 4 drug MC regimen in pediatric patients with refractory or relapsing various tumors types.

Setting: From November 2008 to December 2010, in three academic pediatric oncology centers, 16 children (median age 12 years old; range 5.5-20) were included in this pilot study. This treatment was proposed to children with refractory disease for whom no further effective treatments were available. Most frequent diagnosis were medulloblastoma/cerebral PNET (5) osteosarcoma (5), and one case each of nephroblastoma, high grade glioma, Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma and kidney rhabdoid tumour. The MC regimen consisted in cycles of 56 days (8 weeks) with weekly vinblastine 3 mg/m² (week 1-7), daily cyclophosphamide 30 mg/m² (days 1-21), and twice weekly methotrexate 10 mg/m² (days 21-42), and daily celecoxib 100 mg to 400 mg twice daily (days1-56) followed by a 2-weeks chemotherapy break. Adverse events were determined through laboratory analysis and investigator observations.

Results: One objective response was observed in a patient with Hodgkin lymphoma, and 4 patients experienced disease stabilization and continued their treatment for 3 cycles (24 weeks) or more. At last follow-up, 7 patients (43%) are alive including 1 still undergoing treatment. During the overall 36 cycles of treatments received by patients, 4 grade IV toxicities and 24 grade III toxicities were observed in 11 cycles in only 10 different patients.

Conclusion: The metronomic regimen we report here was well tolerated and associated with disease stabilization. This regimen is currently being evaluated in a national multicenter phase II study.

INTRODUCTION

Metronomic chemotherapy (MC) is defined as the frequent administration of chemotherapy drugs at doses below the single maximal tolerated dose and with no prolonged drug-free breaks [1]. MC has been reported...
to significantly reduce adverse events (AEs) usually associated with chemotherapy. Although clinical data of MC in pediatric oncology remains sparse [1, 2], this approach may be well suited and represents a genuine alternative solution for children with poor prognosis or refractory disease [3, 4], potentially as a maintenance therapy following multimodal treatment [5]. Furthermore, its low cost and limited toxicity make MC a very attractive therapeutic option in low- and middle-income countries [6, 7].

Here, we aimed at developing a new multidrug metronomic protocol for children, integrating the different mechanisms of action of MC. Indeed, although MC had initially been considered to be an anti-angiogenic therapy [8], recent findings have highlighted new effects, which all likely contribute to treatment efficacy [1]. These effects include the stimulation of the anticancer properties of the immune system, re-induction of tumor dormancy as well as potential direct effects against cancer cells [1, 9].

The potential of etoposide and temozolomide used in a metronomic fashion has already been reported [3, 4, 5, 10]. However, since potential mutagenic effects, including myelodysplasia and secondary leukemias, were reported with these agents when administered at more conventional dosing [11, 12], they were not included in this study. Instead, we designed a metronomic regimen relying mainly on oral medications and used a continuous low-dose methotrexate (MTX) / low-dose cyclophosphamide backbone published in 2002 by Colleoni et al. [13]. Lower doses of cyclophosphamide were used to avoid high hematologic toxicities since cyclophosphamide was combined with others anticancer agents. Vinblastine, which had already been included in metronomic protocols [14, 15], was also added to our protocol. This drug only adds little hematological toxicity at the dosage of 3mg/m² and microtubule-targeting agents are known to be the most potent Anti-angiogenic chemotherapeutics so far [16, 17] and bring potential beneficial immunologic effect [18]. Lastly, celecoxib has been added as a 4th agent in this metronomic combination. Celecoxib has been part of most pediatric metronomic regimen [3, 4, 5, 10, 14] as it adds potential anti-angiogenic effect and tumor sensitization to chemotherapy [19] and very limited toxicity. Here, we report of a pilot study of a 4 drug metronomic regimen in children with relapsing, refractory solid tumors.

**PATIENTS AND PROTOCOL**

This pilot study evaluated the use of MC with cycles consisting of weekly intravenous vinblastine 3 mg/m² (week 1 to 6 (later changed to 7 see below)), daily oral cyclophosphamide 30 mg/m² (days 1-21), twice weekly oral MTX 15 mg/m² (then lowered to 10 mg/m² see below) (days 21-42), and twice daily oral celecoxib 100-400 mg (days 1-42), followed by a 2-week therapy break (celecoxib was then kept during the break see below). All families gave consent before enrollment of the patients in the study. This treatment was proposed to children, aged from 3 to 21 years old, with refractory or relapsing cancer following treatment protocols available in our institutions, or to patients who were not eligible for phase I or II trials. All patients with an uncontrolled concurrent illness, active infection or unable to swallow oral medication were excluded from the study. Adverse events (AEs) were determined through laboratory analyses and investigator observations and grade using the NCI-CTC 3.0 criteria. Treatment was terminated upon tumor progression, following physician’s decision, according to parent’s will or due to unacceptable toxicity. Tumor size was evaluated using bidimensional measurement. Disease status evaluated using WHO response criteria.
From November 2008 to December 2010, 16 patients were included in this study, with a median age of 12 years old (5.5-20 years). There were 11 boys and 5 girls. Details of the study population and outcomes are reported in table 1.

The treatment plan was slightly modified after treatment of the first 3 patients upon toxicity and clinical outcome. Thus, and following disease progression -suggesting active neo-angiogenesis during chemotherapy break-, it was decided to continue celecoxib administration between two cycles. A seventh vinblastine administration was also added on day 42. Then, as oral mucositis occurred during the second part of the cycle during which patients were taking oral methotrexate and celecoxib, methotrexate dosage was diminished from 15 mg/m² to 10 mg/m². Overall, 10 out of the 16 patients received the last implemented version of the regimen.

RESULTS

At the end of the observation period, the mean duration of treatment was 17 +/- 14 weeks with 1 patient still on treatment. 7 out of 16 patients are alive with a mean follow-up of 28 +/- 15 weeks. Mean washout period was 5.6 +/- 7 weeks. The best response observed was one objective response in a child with Hodgkin disease who received a modified version of the protocol. Four disease stabilizations (25%) that lasted 24 weeks or more were also observed. All these patients received the implemented version of the regimen. Besides, rapid tumor progression was noted in 4 patients (25%) who did not complete the first cycle of treatment. When comparing time to progression (TTP) while receiving the experimental metronomic regimen with TTP during the previous line of treatment [20,21], we found that TTP obtained with the experimental MC was longer in 8 patients (50%) (see table 1). However, overall there was no statistically significant difference between TTPs for respectively previous and current metronomic treatment (means 12.5 vs 17.1 weeks; Wilcoxon test, p=0.35).

Of particular interest, in 11 patients a decrease in pain and antalgic drug administration was rapidly observed after initiation of the metronomic treatment.

Most importantly, according to the National Cancer Institute Common Toxicity Criteria 3.0, with 24 grade-III and only 4 grade-IV AEs, tolerability was acceptable. They were mainly hematological (83 % of toxicities and 75% of children). Six patients did not display any grade III or IV toxicities. It may be worthwhile to note that 4 of the patients (those with prior high dose chemotherapy followed by hematologic peripheral stem cell transplantation) accounted for 50% of all the AEs. No alopecia was reported and in all children except 1 who previously received high-dose chemotherapy, normal hair growth was noted. No grade III or IV nausea or vomiting was observed. Details are given in table 2. No patients stopped their treatment as a result of toxicity. Vinblastine dosage had to be reduced by 30% in 3 patients because of peripheral neurotoxicity (1 patient) and severe hematological toxicity (2 patients). Celecoxib was stopped in 2 patients due to renal insufficiency in one case and hemoptysis (related to lung metastases) in the other, and MTX dosage was reduced in 4 patients because of grade II or III mucositis.

| Toxicity                             | Number of episodes | Number of patients |
|--------------------------------------|--------------------|--------------------|
| Absolute neutrophil count (>500-1000 G/L) | 24                 | 10                 |
| Hemoglobin (6.5-8.0 g/dL)            | 6                  | 4                  |
| Leukocytes (1,000-2,000 G/L)         | 4                  | 3                  |
| Neutropathy                          | 7                  | 5                  |
| Mucositis                            | 1                  | 1                  |
| Renal Insufficiency                  | 1                  | 1                  |
| Platelets (10,000-50,000 G/L)        | 3                  | 2                  |
| Absolute neutrophil count (>500-1000 G/L) | 2                  | 1                  |
| Platelets < 10,000 G/L               | 2                  | 2                  |

Table 2: Grade III/IV toxicities observed during the metronomic chemotherapy protocol.
DISCUSSION

We report here the results of a 4-drug metronomic regimen in children with relapsing or refractory solid tumors. Of note, the treatment was also proposed to children at very high-risk of relapse, so that 3 patients received this treatment as a maintenance therapy (Table 1). Interestingly, 2 out of these 3 patients received the treatment for almost a year. For one patient the treatment is still ongoing. The second patient relapsed 2 months after stopping maintenance suggesting it may have been stopped to early as previously reported in a patient with medulloblastoma treated with the COMBAT regimen (22).

Table 1: Patients characteristics and treatment outcomes.

| Pt nb | Sex | Tumour Type        | Indication | Age (year) | Weight (kg) | Previous Lines of Treatment | Previous Treatments | Metronomic | Last TTP | Time on treatment | Best Response | Response | Follow-up | Status |
|-------|-----|-------------------|------------|------------|-------------|-----------------------------|----------------------|-------------|----------|-------------------|--------------|----------|------------|--------|
| 1     | M   | Medulloblastoma   | PD         | 5.5        | 16          | 3                          | yes                  | yes        | 8        | 8                 | PD           | 17       | DOD        |        |
| 2     | M   | Rhabdoid Renal Tumor | PD         | 12         | 23          | 3                          | no                   | yes        | 6        | 13                | PD           | 33       | DOD        |        |
| 3     | M   | Medulloblastoma   | PD         | 9          | 22          | 3                          | no                   | yes        | 8        | 14                | PD           | 52       | AWD        |        |
| 4     | F   | Osteosarcoma      | M*         | 11.5       | 43          | 3                          | no                   | no         | no       | 6                 | 52           | CR       | 68        | AWD    |
| 5     | M   | Neuroblastoma     | M          | 6          | 20          | 4                          | no                   | yes        | COMBAT  | 6                 | 8            | PD       | 12        | DOD    |
| 6     | M   | Nephroblastoma    | M          | 12         | 46          | 4                          | yes                  | yes        | no       | 5                 | 14           | PD       | 22        | DOD    |
| 7     | F   | Osteosarcoma      | M          | 16         | 40          | 3                          | no                   | no         | no       | 25                | 6            | PD       | 14        | DOD    |
| 8     | M   | RMS               | M**        | 20         | 54          | 2                          | no                   | yes        | mvb-cyclo//tmz | 16           | 52       | CR         | 56     | CR    |
| 9     | F   | Osteosarcoma      | M***       | 16         | 52          | 2                          | no                   | no         | no       | 6                 | 24           | CR       | 72        | AWD    |
| 10    | M   | Hodgkin Lymphoma  | PD         | 18         | 45          | 4                          | yes****              | yes        | no       | ?                 | 20           | PR       | 24        | AWD    |
| 11    | M   | Glioblastoma      | PD         | 9.5        | 44          | 3                          | no                   | yes        | trz      | 4                 | 6            | PD       | 6         | DOD    |
| 12    | F   | Medulloblastoma   | PD         | 12         | 34          | 3                          | no                   | yes        | etoposide | 6             | 6            | PD       | 16        | DOD    |
| 13    | F   | Supratentorial PNET | PD         | 11         | 30          | 2                          | yes                  | yes        | no       | 34                | 14           | PD       | 27        | AWD    |
| 14    | M   | Medulloblastoma   | PD         | 14         | 24          | 4                          | no                   | yes        | no       | 32                | 6            | PD       | 22        | DOD    |
| 15    | M   | Osteosarcoma      | PD         | 10         | 56          | 3                          | no                   | no         | no       | 12                | 14           | PD       | 30        | DOD    |
| 16    | M   | Osteosarcoma      | PD         | 8.5        | 27          | 1                          | no                   | no         | no       | 84                | 24           | PD       | 25        | AWD    |

SD: Stable Disease; PD: Progressive Disease; AWD: Alive With Disease; DOD: Died Of Disease; M: Maintenance; Nvb: Navelbine; Tmz: Temozolomide; Cyclo: Cyclophosphamide; N.A.: Not Available

*: this patient had a primary refractory metastatic osteosarcoma that progressed during the 2 first lines of chemotherapy. Metronomic chemotherapy was proposed as a maintenance therapy after obtaining surgical complete remission of the primary tumour and bilateral lung metastasis. Monthly zoledronic acid was associated to the metronomic treatment.

**: this patient had a third metastatic relapse of rhabdomyosarcoma. Metronomic maintenance was proposed after obtaining surgical CR and irradiation of the metastatic site.

***: this patient with Hodgkin lymphoma underwent both high dose chemotherapy followed by peripheral blood stem cell transplantation for a relapse and autologous bone marrow transplantation for a subsequent relapse.

$\ddagger$: patients with Li Fraumeni syndrome who developed an osteosarcoma as a third tumor.

In children, who received the protocol as maintenance therapy and who were in CR at treatment initiation, the best status was considered as stable disease.
Treatment tolerance was similar to what has been reported with previous multi-drug metronomic regimens in pediatric populations [3, 4, 5, 10]. Mostly grade III/IV hematological toxicities were observed in 10 patients. It may be worthwhile to note that ¼ of the patients (those with prior high dose chemotherapy followed by peripheral hematopoietic stem cells transplantation) accounted for 50% of all the AEs. Six out of 16 patients (37.5%) did not display any grade III or IV toxicities. Therefore, this regimen is well tolerated in children and also allows treatment of previously very heavily treated who may not have been able to tolerate further MTD chemotherapy.

The initial combination of celecoxib and low dose MTX led to mucositis in 2 out of the 3 first treated patients. Although no pharmacokinetics study was performed to confirm the deleterious interaction between these two drugs, and despite the fact that cox-2 inhibitors did not change low-dose MTX pharmacokinetics in adults [23], it was decided to lower the doses of MTX. After the decrease in MTX dosage, the tolerance of the regimen was indeed improved and no further mucositis were observed.

One radiological response was noted after 2 cycles in a patient with Hodgkin lymphoma and 4 disease stabilizations were observed, according to classic WHO criteria. Although partial and complete responses have been reported in children receiving metronomic chemotherapy [3, 4, 5, 24], this type of therapy may more likely lead to tumor stabilizations [3, 4, 7, 10, 14]. In this regard it should be noted that the RECIST or WHO criteria may not be adapted in the evaluation of anti-angiogenic therapies [25]. Indeed, anti-angiogenic treatments are mainly considered as cytostatic, and as such are most likely to inhibit tumor progression rather than induce tumor regression. When considering the time to progression (TTP), which defines a clinical benefit by comparing the TTP while the patient is receiving the therapy immediately before the treatment of interest versus the TTP while under the experimental treatment, we found that the experimental MC regimen was associated with a longer TTP in 8 patients as compared to the previous lines of treatment. Such analysis of TTP paves the way for new clinical trial design to evaluate the efficacy of non-cytotoxic therapies such as metronomic treatments, which are less likely to produce tumor response assessed with RECIST.

Besides its potential effect in restraining tumor progression, MC seems to be able to help controlling pain in children with cancer. We previously reported fast improvement in pain control in children under MC [10] and Kivivuori et al. reported that MC could also help controlling pain symptoms in children with inoperable brainstem gliomas [26]. In the present study, we reported similar findings as 11 children (69%) experienced less pain, thus leading to a decrease in antalgic treatment, confirming the potential interest of MC in the palliative setting as already well established with for instance oral etoposide.

Among the 16 patients who were treated with this metronomic regimen, 7 had previously received MC, which mainly consisted in oral etoposide alone or combined with other metronomic agents. Interestingly, in these patients, TTP was equal or longer with the new metronomic protocol when compared to TTP with the previous metronomic regimen. Furthermore, patients for whom previous metronomic treatment helped controlling their disease also seemed to have their disease stabilized for longer period with the 4-drug regimen tested here, suggesting that cross resistance between metronomic regimens may not be systematic, opening the way for potential treatment with several lines of MC regimens and also re-challenge with the same treatment as recently reported by Sterba et al. [22].

Compliance is an important issue when considering oral treatments; we did not evaluate compliance in this study. Nevertheless, patients were always present for the planned dose of vinblastine injections suggesting a good adherence to treatment, although compliance with daily oral drugs and weekly injections are different type of constraints.

**CONCLUSION**

The 4-drug regimen we report in this study was well tolerated. Although, efficacy cannot be fully assessed due to the small number of patients who were treated, the longer TTP observed when compared to previous lines of treatment strongly suggests a potential interest in children with refractory disease. A prospective national multicentric phase II study with ancillary biologic study is currently under way (clinicaltrial.gov - NCT01285817) as a result of this pilot study.

**REFERENCES**

1. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nature Rev Clin Oncol. 2010; 7: 455-65.

2. Pasquier E, Kieran MW, Sterba J, Shaked Y, Baruchel S, Oberlin O, Kivivuori MS, Peyrl A, Diawarra M, Casanova M, Zacharoulis S, Vassal G, Berthold F, Verschuur A, André N. Moving forward with metronomic treatments: meeting report of the 2nd international workshop on metronomic and anti-angiogenic chemotherapy in paediatric oncology. Transl Oncol. 2011; 4: 189–97.

3. Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, Neuberg D, Browder T, Folkman J. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005; 27: 573-81.

4. Sterba J, Valik D, Mudry P, Kepak T, Pavelka Z, Bajciova H. Hematol Oncol. 2005; 27: 573-81.
V, Zitterbart K, Kadlecova V, Mazanek P. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie. 2006; 29: 308-13.

5. Choi JMR, Kamani N, La Fond D, Packer RJ, Santi MR, Macdonald TJ. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors. Pediatr Blood Cancer. 2008; 50: 970-5.

6. Traore F, Diawara M, Pasquier E, André N. Children Treated With Metronomic Chemotherapy in a Low-income Country: METRO-MALI-01. Pediatr Hematol Oncol. 2011; 33: 31-4.

7. Klement GL, Kamen BA. Nontoxic, Fiscally Responsible, Future of Oncology: Could it be Beginning in the Third World? J Pediatr Hematol Oncol. 2011; 33:1-3.

8. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4: 23-36.

9. André N, Pasquier E. Response to ‘Intermittent androgen blockade should be regarded as standard therapy in prostate cancer’. Nat Clin Pract Oncol. 2009; 6(2):E1.

10. André N, Rome A, Coze C, Padovani L, Pasquier E, Camoin L, Gentet JC. Metronomical Etoposide/Cyclophosphamide/ Celoxocib regimen given to children with refractory cancer: a preliminary monocentric study. Clin Pharm. 2008; 30: 1336-40.

11. Le Deley MC, Vassal G, Taïbi A, Shamisaldin A, Leblanc T, Hartmann O. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatr Blood Cancer. 2005; 45: 25-31.

12. Dufour C, Da Costa L, Auger N, Jullien M, Bhangoo. J. Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report. J Pediatr Hematol Oncol. 2008; 30: 857-9.

13. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzi G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsh A. Low-dose oral metothrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002; 13: 73-80.

14. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel S. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol. 2006; 28: 720-8.

15. Skapek SX, Ferguson WS, Granowetter L, Devidas M, Perez-Atayde AR, Dehner LP, Hoffer FA, Speights R, Gebhardt MC, Dahl GV, Grier HE; Pediatric Oncology Group. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007; 25: 501-6.

16. Pasquier E, André N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets. 2007; 7: 566-81.

17. Mabeta P, Pepper MS. A comparative study on the anti-angiogenic effects of DNA-damaging and cytokindependent-disrupting agents. Apoptosis. 2009; 12: 81-90.

18. Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 2009; 69: 6987-94.

19. Ponthan F, Wickström M, Gleissman H, Fuskevåg OM, Segerström L, Sveinbjörnsson B, Redfern CP, Eksborg S, Kogner P, Johnsen JI. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res. 2007; 13: 1036-44.

20. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials. 2000; 21:343–59.

21. Kravitz RL, Duan N, Niedzinski EJ, Hay MC, Subramanian SK, Weisner TS. What ever happened to N-of-1 trials? Insiders’ perspectives and a look to the future. Milbank Q. 2008; 86: 533-55.

22. Sterba J, Pavelka Z, André N, Ventruba J, Skotakova J, Bajciová V, Bronisova D, Dubska L, Valik D. Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy. Pediatr Blood Cancer. 2010; 54: 616-17.

23. Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol. 1999; 26: 2539-43.

24. Minturn JE, Janss AJ, Fisher PG, Allen JC, Patti R, Phillips PC, Belasco JB. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer. 2011; 56: 39-44.

25. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009; 45: 228–47.

26. Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009; 45: 228–47.